Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases
Recruiting now
Conditions studied: Cardiovascular Diseases (CVD)
In brief
FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET/CMR provides comprehensive cardiac assessment without extra radiation. This advanced imaging approach improves diagnosis and personalized treatment for better patient outcomes.
Key facts
- Study ID
- NCT07063043
- Run by
- Shanghai East Hospital
- People needed
- 40
- Starts
- 2024-12-01
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2025-07-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Participants must have a confirmed clinical diagnosis of cardiovascular disease by a cardiologist, based on genetic testing, family history, and comprehensive clinical evaluation including physical examination, echocardiography, and when indicated, cardiac MRI findings.
- Age requirement: >18 years.
- Patients should demonstrate stable cardiovascular status without significant changes in symptoms, treatment, or clinical findings for a specified pre-enrollment period.
- Participants must be capable of providing informed consent and willing to adhere to all study requirements, including follow-up procedures.
You may not qualify if…
- History of malignancy
- Documented cardiovascular diseases, including coronary artery disease, myocardial infarction, or related conditions
- Implanted metallic devices (e.g., pacemakers, aneurysm clips) or other MRI-incompatible medical prostheses
- Claustrophobia
- Pregnancy or lactation
- Known hypersensitivity to gadolinium-based contrast agents
- Renal impairment (eGFR <30 mL/min/1.73m² by CKD-EPI equation)
Where it is running
- Shanghai East Hospital — Shanghai, Shanghai Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.